{"id":"W2761819177","doi":"10.1093/annonc/mdx365.080","title":"IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Atezolizumab; Paclitaxel; Triple-negative breast cancer; Oncology; Placebo; Internal medicine; Breast cancer; Chemotherapy; Cancer; Immunotherapy; Pathology; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00157256,0.001593359,0.002742694,0.0004874007,0.0004397318,0.001273985,0.001608822,0.001878071,0.007081835],"category_scores_gemma":[0.001371979,0.0008049817,0.002416909,0.0004850293,0.001261173,0.001085773,0.0005520293,0.005265756,0.001624455],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000987075,"about_ca_system_score_gemma":0.001712822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00119407,"about_ca_topic_score_gemma":0.003854494,"domain_scores_codex":[0.9995403,0.0002350162,0.0000221229,0.0000832399,0.00003416964,0.00008507413],"domain_scores_gemma":[0.9991947,0.0002113575,0.0001385716,0.00007417583,0.00003786042,0.0003434233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9214734,0.0241824,0.001270174,0.0006403579,0.001320982,0.00006705593,0.00009451704,0.0008051145,0.009130392,0.0002062222,0.002071979,0.03873742],"study_design_scores_gemma":[0.7989928,0.1937989,0.003366155,0.00003444522,0.0006187337,0.00008442264,0.00003217968,0.0004711399,0.001056392,0.0001583536,0.001361672,0.00002478296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9828686,0.004074773,0.0008898045,0.001220783,0.0006016075,0.003054303,0.002612924,0.0002343248,0.004442944],"genre_scores_gemma":[0.9770588,0.003276011,0.002363425,0.00214154,0.0006561573,0.003126273,0.004479569,0.00008605195,0.006812239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007081835,"threshold_uncertainty_score":0.02369112,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09233901511981349,"score_gpt":0.4434485724497312,"score_spread":0.3511095573299178,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}